Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.59 Insider Own3.62% Shs Outstand55.10M Perf Week2.40%
Market Cap94.22M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float53.11M Perf Month27.61%
Income-87.26M PEG- EPS next Q-0.27 Inst Own7.22% Short Float0.10% Perf Quarter35.71%
Sales0.00M P/S- EPS this Y150.35% Inst Trans-14.48% Short Ratio0.44 Perf Half Y32.56%
Book/sh2.32 P/B0.74 EPS next Y-234.51% ROA-46.09% Short Interest0.05M Perf Year47.41%
Cash/sh2.38 P/C0.72 EPS next 5Y- ROE-51.10% 52W Range0.53 - 2.84 Perf YTD44.92%
Dividend Est.- P/FCF- EPS past 5Y-39.81% ROI-68.01% 52W High-39.79% Beta-0.36
Dividend TTM- Quick Ratio9.26 Sales past 5Y0.00% Gross Margin- 52W Low219.81% ATR (14)0.21
Dividend Ex-Date- Current Ratio9.26 EPS Y/Y TTM27.23% Oper. Margin0.00% RSI (14)53.00 Volatility12.50% 12.47%
Employees81 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.04
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q50.60% Payout- Rel Volume0.00 Prev Close1.71
Sales Surprise-100.00% EPS Surprise-140.19% Sales Q/Q- EarningsApr 16 AMC Avg Volume122.69K Price1.71
SMA205.10% SMA506.33% SMA20039.50% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-04-24Initiated H.C. Wainwright Buy $7
Apr-13-21Initiated SVB Leerink Outperform $32
Apr-13-21Initiated Piper Sandler Overweight
Apr-13-21Initiated Jefferies Buy $27
May-22-24 04:05PM
May-07-24 06:30AM
May-02-24 02:33PM
Apr-16-24 04:05PM
Mar-19-24 08:30AM
04:30PM Loading…
Feb-12-24 04:30PM
Dec-12-23 06:00AM
Dec-11-23 04:05PM
Nov-30-23 09:45AM
Nov-28-23 09:40AM
Nov-21-23 07:32AM
Nov-20-23 04:41PM
Nov-06-23 09:40AM
09:40AM Loading…
Oct-20-23 09:40AM
Sep-15-23 12:00PM
Sep-12-23 04:15PM
Aug-24-23 06:21PM
Jul-10-23 08:00AM
Jul-05-23 04:05PM
Jun-01-23 04:05PM
Apr-11-23 04:05PM
Mar-20-23 09:24AM
Mar-18-23 02:40PM
Mar-17-23 04:38PM
Mar-06-23 08:15AM
Feb-06-23 08:30AM
05:13AM Loading…
Jan-16-23 05:13AM
Dec-30-22 07:30AM
Dec-19-22 08:00AM
Dec-02-22 05:00PM
Oct-27-22 04:05PM
Oct-04-22 11:40AM
Oct-03-22 04:10PM
Sep-13-22 04:30PM
Sep-01-22 08:00AM
Aug-30-22 09:36AM
Aug-08-22 12:19PM
Jul-12-22 06:02AM
Jul-11-22 04:05PM
Jun-17-22 04:05PM
Jun-08-22 12:00PM
Jun-02-22 04:05PM
May-17-22 04:05PM
May-04-22 07:43AM
May-03-22 04:05PM
May-02-22 02:02PM
Mar-31-22 04:05PM
Mar-01-22 08:00AM
Feb-09-22 07:00AM
Jan-24-22 07:00AM
Jan-05-22 07:00AM
Jan-04-22 04:05PM
Dec-25-21 02:38AM
Nov-25-21 07:35AM
Nov-22-21 08:00AM
Nov-19-21 02:47PM
Nov-18-21 04:02PM
Nov-11-21 08:00AM
Oct-19-21 08:00AM
Sep-08-21 08:00AM
Sep-02-21 08:00AM
Aug-31-21 04:05PM
Aug-25-21 08:00AM
Aug-23-21 04:05PM
Jun-11-21 03:57PM
May-26-21 08:00AM
May-25-21 08:00AM
May-12-21 08:00AM
Apr-08-21 08:00AM
Mar-23-21 04:05PM
Mar-18-21 11:58PM
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.